Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Articles in PharmaTimes

In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.

April 2014

NHS England to fund hepatitis C drug Sovaldi

February 2014

B-MS oral HCV combo gets FDA breakthrough status

January 2014

Gilead's HCV drug Sovaldi gets Europe OK

December 2013

AbbVie hep C drug cures 96% of patients in 12 weeks

Gilead's HCV drug gets green light in USA

November 2013

Thumbs-up for J&J drugs Olysio and Invokana

BI HCV drug faldaprevir shows promise

October 2013

Vertex cuts workforce by 15% as HCV drug declines

Gilead gets FDA panel backing for hep C pill

FDA panel backs J&J/Medivir's hepatitis C drug

Merck & Co hep C combo designated as breakthrough

May 2013

AbbVie hep C combo designated as breakthrough therapy